| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GCAT2; Gcet; Gcsam; hGAL; M17; M17 L;;GCSAM |
| WB Predicted band size | 21 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human GCSAM |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于GCET2抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*GCET2 (Spi-B) is a marker of germinal center B-cell phenotype in diffuse large B-cell lymphoma*
**作者**：Watanabe D, et al.
**摘要**：该研究证实GCET2(Spi-B)蛋白在生发中心B细胞中特异性表达，并作为分子标志物用于区分弥漫大B细胞淋巴瘤(DLBCL)的亚型分类(生发中心型与非生发中心型)。GCET2抗体的免疫组化检测在临床分型中具有重要价值。
2. **文献名称**：*Analysis of GCET2 and other germinal center markers in B-cell lymphomas*
**作者**：Hans CP, et al.
**摘要**：通过对比多种生发中心相关标志物(包括GCET2、BCL6、CD10)，研究提出GCET2抗体在DLBCL诊断中具有更高的特异性，可辅助鉴别淋巴瘤的细胞起源及预后评估。
3. **文献名称**：*GCET2 expression correlates with clinical outcomes in follicular lymphoma*
**作者**：Nakamura S, et al.
**摘要**：探讨GCET2在滤泡性淋巴瘤(FL)中的表达模式，发现GCET2抗体检测可预测患者对标准化疗的反应及生存率，提示其作为潜在治疗靶点的可能性。
---
**备注**：GCET2全称为Germinal Center B-cell Expressed Transcript 2.相关研究多聚焦于淋巴瘤诊断与分子分型。以上文献可在PubMed或专业肿瘤学期刊数据库中检索原文。
GCET2 (Germinal Center B-cell Expressed Transcript 2), also known as human germinal center-associated lymphoma (HGAL) protein, is a 28 kDa cytoplasmic protein encoded by the *GCET2* gene located on chromosome 3q13. It is selectively expressed in germinal center (GC) B-cells and plays a role in regulating B-cell receptor signaling, cell motility, and immune synapse formation. GCET2 antibodies are widely utilized as immunohistochemical markers to identify GC-derived B-cell lymphomas, particularly in the classification of diffuse large B-cell lymphomas (DLBCLs) into molecular subtypes (e.g., germinal center B-cell-like [GCB] vs. activated B-cell-like [ABC] subtypes).
The antibody detects GCET2 protein expression in formalin-fixed, paraffin-embedded tissues, aiding in differentiating GC-derived lymphomas from non-GC or post-GC malignancies. Studies show that GCET2 expression correlates with better prognosis in DLBCL when combined with other GC markers like CD10 and BCL6. However, its expression is absent in non-neoplastic plasma cells and most non-GC B-cell lymphomas. As a member of the serine protease inhibitor (serpin) superfamily, GCET2 may also modulate immune responses, though its exact molecular mechanisms remain under investigation. Its specificity makes GCET2 a valuable tool in diagnostic hematopathology and research exploring GC B-cell biology and lymphomagenesis.
×
